AIDS

Article	Citations
Characteristics and outcomes of COVID-19 in patients with HIV: a multicentre research network study	122
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis	95
Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study	90
Viral suppression rates in a safety-net HIV clinic in San Francisco destabilized during COVID-19	74
Disproportionate burden of coronavirus disease 2019 among racial minorities and those in congregate settings among a large cohort of people with HIV	72
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV	71
Risk of adverse coronavirus disease 2019 outcomes for people living with HIV	67
HIV infection and COVID-19: risk factors for severe disease	64
Impaired antibody response to COVID-19 vaccination in advanced HIV infection	62
The Joint United Nations Programme on HIV/AIDS 95–95–95 targets: worldwide clinical and cost benefits of generic manufacture	55
Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy – naive adults with HIV-1 infection	52
HIV in Iran: onset, responses, and future directions	48
The switch from tenofovir disoproxil fumarate to tenofovir alafenamide determines weight gain in patients on rilpivirine-based regimen	46
Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes	41
Coronavirus disease 2019 and Pneumocystis jirovecii pneumonia: a diagnostic dilemma in HIV	41
Productive HIV infection in astrocytes can be established via a nonclassical mechanism	40
Clinical characteristics, comorbidities and outcomes among persons with HIV hospitalized with coronavirus disease 2019 in Atlanta, Georgia	40
Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment	38
Population-level effectiveness of a national HIV preexposure prophylaxis programme in MSM	37
Safety and antibody response to the first dose of severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine in persons with HIV	37
The People Living with HIV Stigma Index 2.0: generating critical evidence for change worldwide	35
Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan	34
TIGIT is upregulated by HIV-1 infection and marks a highly functional adaptive and mature subset of natural killer cells	34
Community-based delivery of HIV treatment in Zambia: costs and outcomes	34
Antiretroviral drug concentrations in brain tissue of adult decedents	34

Worldwide relative smoking prevalence among people living with and without HIV	33
Virologic efficacy of tenofovir, lamivudine and dolutegravir as second-line antiretroviral therapy in adults failing a tenofovir-based first-line regimen	32
Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents	31
Oral preexposure prophylaxis continuation, measurement and reporting	30
Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection	30
Increasing preexposure prophylaxis use and ‘net prevention coverage’ in behavioural surveillance of Australian gay and bisexual men	30
Tenofovir alafenamide vs. tenofovir disoproxil fumarate: an updated meta-analysis of 14 894 patients across 14 trials	30
Comparison of dementia risk after age 50 between individuals with and without HIV infection	28
Modeling an integrated HIV prevention and care continuum to achieve the Ending the HIV Epidemic goals	28
Adverse perinatal outcomes associated with antiretroviral therapy regimens: systematic review and network meta-analysis	26
Changes in weight and BMI with first-line doravirine-based therapy	26
Presence of asymptomatic cytomegalovirus and Epstein--Barr virus DNA in blood of persons with HIV starting antiretroviral therapy is associated with non-AIDS clinical events	25
Coronavirus disease 2019 attack rate in HIV-infected patients and in preexposure prophylaxis users	25
Factors associated with hospital admission for COVID-19 in HIV patients	25
Dolutegravir/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV	25
High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV – but HIV viremia matters?	24
Clinic-level and individual-level factors that influence HIV viral suppression in adolescents and young adults: a national survey in Kenya	24
Comparative performance of the laboratory assays used by a Diagnostic Laboratory Hub for opportunistic infections in people living with HIV	23
Circulating extracellular vesicles as new inflammation marker in HIV infection	23
HPV vaccination to prevent recurrence of anal intraepithelial neoplasia in HIV+ MSM	23
SARS-CoV-2 infection and coronavirus disease 2019 severity in persons with HIV on antiretroviral treatment	23
Increased infectious-cause hospitalization among infants who are HIV-exposed uninfected compared with HIV-unexposed	23
Adherence, resistance, and viral suppression on dolutegravir in sub-Saharan Africa: implications for the TLD era	22
Is tenofovir disoproxil fumarate associated with weight loss?	22
Projecting the impact of equity-based preexposure prophylaxis implementation on racial disparities in HIV incidence among MSM	22
Safety and Immunogenicity of SARS-CoV-2 vaccines in people with HIV	22
Characteristics and clinical manifestations of monkeypox among people with and without HIV in the United States: a retrospective cohort	21
Household wealth and HIV incidence over time, rural Uganda, 1994–2018	21
A total facility approach to reducing HIV stigma in health facilities: implementation process and lessons learned	21
Association of HIV infection with outcomes among adults hospitalized with COVID-19	20
Recently acquired and early chronic hepatitis C in MSM: Recommendations from the European treatment network for HIV, hepatitis and global infectious diseases consensus panel	20
Preventing HIV outbreaks among people who inject drugs in the United States: plus ça change, plus ça même chose	20
Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens	19
Beta amyloid levels in cerebrospinal fluid of HIV-infected people vary by exposure to antiretroviral therapy	19
Ending an HIV epidemic among persons who inject drugs in a middle-income country: extremely low HIV incidence among persons who inject drugs in Hai Phong, Viet Nam	19
The impact of self-selection based on HIV risk on the cost-effectiveness of preexposure prophylaxis in South Africa	18
The shifting age distribution of people with HIV using antiretroviral therapy in the United States	18
Hospital admissions in individuals with HTLV-1 infection in Spain	18
Viral suppression during COVID-19 among people with HIV experiencing homelessness in a low-barrier clinic-based program	18
Accuracy of self-reported HIV-testing history and awareness of HIV-positive status in four sub-Saharan African countries	18
Exploring patterns and predictors of suicidal ideation among pregnant and postpartum women living with HIV in Kilimanjaro, Tanzania	18
Screening strategies for the detection of anal high-grade squamous intraepithelial lesions in women living with HIV	18
Progress toward HIV elimination goals: trends in and projections of annual HIV testing and condom use in Africa	18
Incidence and risk factors for recurrent sexually transmitted infections among MSM on HIV pre-exposure prophylaxis	18
Structural determinants of HIV/STI prevalence, HIV/STI/sexual and reproductive health access, and condom use among immigrant sex workers globally	18
An updated meta-analysis on the association between HIV infection and COVID-19 mortality	18
Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV	18
Pharmacokinetics of darunavir and cobicistat in pregnant and postpartum women with HIV	17
Incidence, clearance, persistence and factors related with high-risk anal HPV persistence in South-East Asian MSM and transgender women	17
COVID-19 vaccine immunogenicity in people with HIV	17

The COVID-19 pandemic as a catalyst for differentiated care models to end the HIV epidemic in the United States: applying lessons from high-burden settings	17
Using longitudinal genetic-network study to understand HIV treatment-as-prevention	17
Proliferation of HIV-infected renal epithelial cells following virus acquisition from infected macrophages	17
Clinic and care: associations with adolescent antiretroviral therapy adherence in a prospective cohort in South Africa	17
Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV	17
Impact of long-acting therapies on the global HIV epidemic	17
Mapping the extent of heterogeneity of human CCR5+ CD4+ T cells in peripheral blood and lymph nodes	17
Long noncoding RNA HOTAIRM1 promotes myeloid-derived suppressor cell expansion and suppressive functions through up-regulating HOXA1 expression during latent HIV infection	17
Performance of a short, self-report adherence scale in a probability sample of persons using HIV antiretroviral therapy in the United States	17
Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy	17
Telemedicine and visit completion among people with HIV during the coronavirus disease 2019 pandemic compared with prepandemic	17
Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options	16
Increase in HIV incidence in women exposed to rape	16
Placental transfer of the integrase strand inhibitors cabotegravir and bictegravir in the ex-vivo human cotyledon perfusion model	16
The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy	16
Weight gain stopping/switch rules for antiretroviral clinical trials	16
Asymptomatic neurocognitive impairment is a risk for symptomatic decline over a 3-year study period	16
Effects of an intervention on internalized HIV-related stigma for individuals newly entering HIV care	16
Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy	16
Decision-making regarding condom use among daily and event-driven users of preexposure prophylaxis in the Netherlands	16
Curable sexually transmitted infections among women with HIV in sub-Saharan Africa	16
Effects of anticholinergic medication use on brain integrity in persons living with HIV and persons without HIV	16
A taxonomy of pragmatic measures of HIV preexposure prophylaxis use	16
Risk of HIV infection among adolescent girls and young women in age-disparate relationships in sub-Saharan Africa	15
Higher prevalence of stunting and poor growth outcomes in HIV-exposed uninfected than HIV-unexposed infants in Kenya	15
Depression and HIV viral nonsuppression among people engaged in HIV care in an urban clinic, 2014–2019	15
Adherence to daily HIV pre-exposure prophylaxis in a large-scale implementation study in New South Wales, Australia	15
HIV-1 viral blips are associated with repeated and increasingly high levels of cell-associated HIV-1 RNA transcriptional activity	15
Declines in HIV prevalence in female sex workers accessing an HIV treatment and prevention programme in Nairobi, Kenya over a 10-year period	15
High abundance of genus Prevotella is associated with dysregulation of IFN-I and T cell response in HIV-1-infected patients	15
Variation in estimated viral suppression associated with the definition of viral suppression used	15
SARS-CoV-2 incidence, testing rates, and severe COVID-19 outcomes among people with and without HIV	15
HIV disease duration, but not active brain infection, predicts cortical amyloid beta deposition	15
Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era	15
Coronavirus disease 2019 vaccine effectiveness among a population-based cohort of people living with HIV	15
Potential impact of COVID-19 in people living with HIV: experience from previous 21st century coronaviruses epidemics	15
Markers of inflammation and immune activation are associated with lung function in a multi-center cohort of persons with HIV	15
Impact of HIV infection on baseline characteristics and survival of women with breast cancer	15
Intersectional stigmas and HIV-related outcomes among a cohort of key populations enrolled in stigma mitigation interventions in Senegal	15
HIV influences microtubule associated protein-2: potential marker of HIV-associated neurocognitive disorders	14
Late presentation for HIV impairs immunological but not virological response to antiretroviral treatment	14
False-positive HIV screening test in a patient with pulmonary embolism because of severe acute respiratory syndrome coronavirus 2 infection	14
Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIV	14
Pharmacokinetics of tenofovir alafenamide with and without cobicistat in pregnant and postpartum women living with HIV	14
Internalized stigma among people living with HIV: assessing the Internalized AIDS-Related Stigma Scale in four countries	14
Low CD4+ cell count nadir exacerbates the impacts of APOE ε4 on functional connectivity and memory in adults with HIV	14
Utilizing electronic health record data to understand comorbidity burden among people living with HIV: a machine learning approach	14
Advanced HIV disease in the Botswana combination prevention project: prevalence, risk factors, and outcomes	14
Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa	14
A systematic review of early adoption of implementation science for HIV prevention or treatment in the United States	13
Mechanistic differences underlying HIV latency in the gut and blood contribute to differential responses to latency-reversing agents	13
Semen virome of men with HIV on or off antiretroviral treatment	13
Modeling the cost-effectiveness of point-of-care platforms for infant diagnosis of HIV in sub-Saharan African countries	13
Evaluation of the POP-UP programme: a multicomponent model of care for people living with HIV with homelessness or unstable housing	13
Multimorbidity networks associated with frailty among middle-aged and older people with HIV	13
Differential impact of antiretroviral therapy initiated before or during pregnancy on placenta pathology in HIV-positive women	13
Associations between methamphetamine use and lack of viral suppression among a cohort of HIV-positive persons who inject drugs in Hai Phong, Vietnam	13
Drug resistance mutations in HIV provirus are associated with defective proviral genomes with hypermutation	13
Assessing comorbidities and survival in HIV-infected and uninfected matched Medicare enrollees	13
Achieving maternal viral load suppression for elimination of mother-to-child transmission of HIV in South Africa	13
Limitations of the UNAIDS 90-90-90 metrics: a simulation-based comparison of cross-sectional and longitudinal metrics for the HIV care continuum	13
Employing telehealth within HIV care: advantages, challenges, and recommendations	13
Surrogate neutralization responses following severe acute respiratory syndrome coronavirus 2 vaccination in people with HIV: comparison between inactivated and mRNA vaccine	13
Increased monocyte and T-cell activation in treated HIV+ Ugandan children: associations with gut alteration and HIV factors	13
Novel population-level proxy measures for suboptimal HIV preexposure prophylaxis initiation and persistence in the USA	13
Switching from tenofovir alafenamide to tenofovir disoproxil fumarate improves lipid profile and protects from weight gain	13
Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa	13
A comparative study of classic and HIV-viremic and aviremic AIDS Kaposi sarcoma	12
Sterol metabolism modulates susceptibility to HIV-1 Infection	12
Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV	12
Comparison of dementia incidence and prevalence between individuals with and without HIV infection in primary care from 2000 to 2016	12
Longitudinal association between intimate partner violence and viral suppression during pregnancy and postpartum in South African women	12
Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysis	12
HIV stigma by association among Australian gay and bisexual men	12
Severe intimate partner violence is associated with all-cause mortality among women living with HIV	12
Tenofovir disoproxil fumarate/emtricitabine and severity of coronavirus disease 2019 in people with HIV infection	12
Internalized HIV stigma predicts subsequent viremia in US HIV patients through depressive symptoms and antiretroviral therapy adherence	12
The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa	12
Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens	12
The effect of universal testing and treatment on HIV stigma in 21 communities in Zambia and South Africa	12

Trends in diabetes incidence and associated risk factors among people with HIV in the current treatment era	12
Robust HIV-specific CD4+ and CD8+ T-cell responses distinguish elite control in adolescents living with HIV from viremic nonprogressors	12
Losartan to reduce inflammation and fibrosis endpoints in HIV disease	12
Interventions to improve daily medication use among adolescents and young adults: what can we learn for youth pre-exposure prophylaxis services?	12
Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV	12
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapy	12
What shapes resilience among people living with HIV? A multi-country analysis of data from the PLHIV Stigma Index 2.0	12
Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1	12
Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes	12
Tuberculosis symptom screening for children and adolescents living with HIV in six high HIV/TB burden countries in Africa	12
Estimating the probability of diagnosis within 1 year of HIV acquisition	11
The other side of screening: predictors of treatment and follow-up for anal precancers in a large health system	11
Clonal hematopoiesis in men living with HIV and association with subclinical atherosclerosis	11
Children who are HIV-exposed and uninfected: evidence for action	11
Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV	11
Cognitive trajectories after treatment in acute HIV infection	11
Incidence of HIV-positive admission and inpatient mortality in Malawi (2012–2019)	11
First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines	11
Performing rapid autopsy for the interrogation of HIV reservoirs	11
Circulating microRNA signatures that predict liver fibrosis progression in patients with HIV-1/hepatitis C virus coinfections	11
Long-term persistence of transcriptionally active ‘defective’ HIV-1 proviruses: implications for persistent immune activation during antiretroviral therapy	11
Liver steatosis and nonalcoholic fatty liver disease with fibrosis are predictors of frailty in people living with HIV	11
A randomized, placebo-controlled, double-blinded clinical trial of colchicine to improve vascular health in people living with HIV	11
Estimated time from HIV infection to diagnosis and diagnosis to first viral suppression during 2014–2018	11
HIV-1 infection of the kidney: mechanisms and implications	11
Determinants of antibody response to severe acute respiratory syndrome coronavirus 2 mRNA vaccines in people with HIV	11
The prevalence of mental health disorders in people with HIV and the effects on the HIV care continuum	11
The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoprox	11
Severe acute respiratory syndrome coronavirus-2 antibody prevalence in people with and without HIV in rural Western Kenya, January to March 2020	10
Persistent HIV transcription and variable antiretroviral drug penetration in lymph nodes during plasma viral suppression	10
Direct maternal deaths attributable to HIV in the era of antiretroviral therapy: evidence from three population-based HIV cohorts with verbal autopsy	10
Distinct forms of migration and mobility are differentially associated with HIV treatment adherence	10
Assessing self-reported discrimination among men who have sex with men (MSM)	10
Aging, trends in CD4+/CD8+ cell ratio, and clinical outcomes with persistent HIV suppression in a dynamic cohort of ambulatory HIV patients	10
Differences in HIV clinical outcomes amongst heterosexuals in the United Kingdom by ethnicity	10
Agreement between self-reported and objective measures of sleep in people with HIV and lifestyle-similar HIV-negative individuals	10
Stigma among key populations living with HIV in the Dominican Republic: experiences of people of Haitian descent, MSM, and female sex workers	10
Using HIV self-testing to increase the affordability of community-based HIV testing services	10
Global estimates for the lifetime cost of managing HIV	10
Determining standardized causes of death of infants, children, and adolescents living with HIV in Asia	10
HIV and risk of dementia in older veterans	10
Impact of the coronavirus disease 2019 pandemic on prescriptions for antiretroviral drugs for HIV treatment in the United States, 2019–2021	10
Syndemics and preexposure prophylaxis are independently associated with rectal immune dysregulation in sexual minority men	10
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria	10
Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients	10
Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa	10
Application of machine-learning techniques in classification of HIV medical care status for people living with HIV in South Carolina	10
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis	10
HIV/AIDS and aging: the new frontier for HIV/AIDS research and care	10
First pharmacokinetic data of bictegravir in pregnant women living with HIV	10
Antiretroviral therapy reduces but does not normalize immune and vascular inflammatory markers in adults with chronic HIV infection in Kenya	10
Antiretroviral therapy-treated HIV-infected adults with coronary artery disease are characterized by a distinctive regulatory T-cell signature	10
Monocyte activation in persons living with HIV and tuberculosis coinfection	10
Financial incentives to increase pediatric HIV testing: a randomized trial	10
Real world use of dolutegravir two drug regimens	10
Integration and scale-up of efforts to measure and reduce HIV-related stigma: the experience of Thailand	10
Assessing layered HIV prevention programming: optimizing outcomes for adolescent girls and young women	9
Immature/transitional B-cell expansion is associated with bone loss in HIV-infected individuals with severe CD4+ T-cell lymphopenia	9
High-risk human papillomavirus test in anal smears: can it optimize the screening for anal cancer?	9
Mathematical modelling of the influence of serosorting on the population-level HIV transmission impact of pre-exposure prophylaxis	9
Fat gain differs by sex and hormonal status in persons living with suppressed HIV switched to raltegravir/etravirine	9
Potential reduction in female sex workers’ risk of contracting HIV during coronavirus disease 2019	9
Changes in HIV preexposure prophylaxis prescribing in Australian clinical services following COVID-19 restrictions	9
Predictors of secondary HIV transmission risk in a cohort of adolescents living with HIV in South Africa	9
Circulating CD4+ TEMRA and CD4+ CD28− T cells and incident diabetes among persons with and without HIV	9
Plasma galectin-9 as a predictor of adverse non-AIDS events in persons with chronic HIV during suppressive antiretroviral therapy	9
Risk factors and outcomes of HIV-associated stroke in Zambia	9
The symptomatology of cerebrospinal fluid HIV RNA escape: a large case-series	9
Mitochondrial DNA haplogroups and weight gain following switch to integrase strand transfer inhibitor-based antiretroviral therapy	9
HIV-associated plasmablastic lymphoma in the era of HAART: a single-center experience of 21 patients	9
Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1-infected patients	9
Point-of-care urine tenofovir testing to predict HIV drug resistance among individuals with virologic failure	9
Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression	9
Efficacy of sotrovimab for persistent coronavirus disease-2019 in a severely immunocompromised person living with HIV	9
The predictors of pain extent in people living with HIV	9
Strategies to improve HIV care outcomes for people with HIV who are out of care	9
Effect of Truvada lawsuit advertising on preexposure prophylaxis attitudes and decisions among sexual and gender minority youth and young adults at risk for HIV	9
Ambient air pollution is associated with vascular disease in Ugandan HIV-positive adolescents	9
Prevalence and risk factors of frailty among adults living with HIV aged 70 years or older	9
A pragmatic approach to managing antiretroviral therapy-experienced patients diagnosed with HIV-associated cryptococcal meningitis: impact of antiretroviral therapy adherence and duration	9
High seroconversion rate and SARS-CoV-2 Delta neutralization in people with HIV vaccinated with BNT162b2	9
Legacy effect on neuropsychological function in HIV-infected men on combination antiretroviral therapy	9
Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women	9
SARS-CoV-2 infection in a highly experienced person living with HIV	9
Identifying HIV-related digital social influencers using an iterative deep learning approach	9
Tenofovir-based PrEP for COVID-19: an untapped opportunity?	9
Deciphering the serological response to syphilis treatment in men living with HIV	9
High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I	9
No significant changes in body fat mass in virologically suppressed, HIV-positive patients switched to lamivudine--dolutegravir	9
Growth deficits in antiretroviral and HIV-exposed uninfected versus unexposed children in Malawi and Uganda persist through 60 months of age	9
Accelerating adolescent HIV research in low-income and middle-income countries: evidence from a research consortium	9
Trends in HIV prevalence by self-report among MSM diagnosed and reported with gonorrhea in six United States jurisdictions from 2010 to 2019	9
Interactive digital interventions for prevention of sexually transmitted HIV	9
Hepatitis delta in patients hospitalized in Spain (1997–2018)	8
Preterm birth and severe morbidity in hospitalized neonates who are HIV exposed and uninfected compared with HIV unexposed	8